- Home
- RXRX vs DFIN Comparison
RXRX vs DFIN Comparison
Compare RXRX & DFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RXRX | DFIN |
|---|---|---|
| Founded | 2013 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.2B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | RXRX | DFIN |
|---|---|---|
| Price | $4.87 | $49.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $8.00 | ★ $63.50 |
| AVG Volume (30 Days) | ★ 23.2M | 274.2K |
| Earning Date | 02-27-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.12 |
| Revenue | $43,689,000.00 | ★ $750,800,000.00 |
| Revenue This Year | $6.74 | N/A |
| Revenue Next Year | $34.31 | $4.20 |
| P/E Ratio | ★ N/A | $44.67 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.79 | $37.80 |
| 52 Week High | $12.36 | $69.93 |
Technical Indicators
Market Signals| Indicator | RXRX | DFIN |
|---|---|---|
| Relative Strength Index (RSI) | 60.38 | 59.29 |
| Support Level | $4.05 | $44.89 |
| Resistance Level | $4.43 | $50.21 |
| Average True Range (ATR) | 0.25 | 1.42 |
| MACD | 0.06 | 0.42 |
| Stochastic Oscillator | 85.42 | 80.64 |
Price Performance
Historical ComparisonAbout RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
About DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.